Instrument Inactif

Communiqués ATHENEXPAR

Actions

ATNX

US04685N2027

Communiqués

22/05/23	ATHENEX, INC. : Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/05/23	Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process	AQ
03/05/23	ATHENEX, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
25/04/23	ATHENEX, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
31/03/23	ATHENEX, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
20/03/23	ATHENEX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
20/03/23	Athenex: Q4 Earnings Snapshot	AQ
20/03/23	Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update	AQ
14/02/23	ATHENEX, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
14/02/23	Athenex Announces a Reverse Stock Split	GL
14/02/23	Athenex Announces a Reverse Stock Split	GL
03/01/23	Athenex Announces MHRA Decision on Oral Paclitaxel	AQ
03/01/23	Athenex Announces MHRA Decision on Oral Paclitaxel	GL
21/12/22	Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel	AQ
20/12/22	Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer	GL
20/12/22	Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer	AQ
16/12/22	Athenex Exits 503B Sterile Compounding Business	GL
16/12/22	Athenex Exits 503B Sterile Compounding Business	AQ
22/11/22	ATHENEX, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22/11/22	Athenex Announces Positive Results of Special Stockholder Meeting	GL
22/11/22	Athenex Announces Positive Results of Special Stockholder Meeting	AQ
21/11/22	ATHENEX, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits (form 8-K)	AQ
21/11/22	Athenex Announces Closing of the Sale of its China API Business	AQ
21/11/22	Athenex Announces Closing of the Sale of its China API Business	GL
08/11/22	Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference	GL